The Coagulation Factors Market is expected to register a CAGR of 6% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.
The research report on the coagulation factors market is segmented by product type into factor VIII, factor IX, factor VII, and others. The report further explores applications such as hemophilia treatment, surgery, and other bleeding disorders. End-users include hospitals, specialty clinics, and research institutions. The global market analysis is broken down by region and major countries, including North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market evaluation is presented in US$ for all segmental analyses.
Purpose of the ReportThe report Coagulation Factors Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Coagulation Factors Market Segmentation
Product Type- Factor VII
- Factor VIII
- Factor IX
- Factor X
- Factor XIII
- Von Willebrand Factor
- Anti-Inhibitor Coagulant Complex
- Hemophilia
- Von Willebrand disease
- Surgery
- Other Bleeding Disorders
- Plasma derived
- Recombinant
- Hospitals and Clinics
- Ambulatory Surgery Centers
- Research Institutes
Strategic Insights
Coagulation Factors Market Growth Drivers- Rising Prevalence of Hemophilia and Bleeding Disorders:
The increasing trend of hemophilia and other coagulation disorder cases worldwide is, therefore, acting as a main driver for this coagulation factors market. According to the World Federation of Hemophilia, more than 1 person in 10,000 have hemophilia A, and the case prevalence is of similar order with other coagulation disorders. A growing patient population, along with the therapeutic needs for controlling and preventing an episode of bleed, is driving up the demand in the coagulation factor drugs market. Screening and diagnostics are being advanced, leading to the discovery of these diseases, thereby further expanding the market. - Advancements in Recombinant Coagulation Factor Products:
The higher safety profile of recombinant coagulation factors compared to plasma-derived products is driving their acceptance. They are free from the risk of transmission of blood-borne infections such as HIV and hepatitis, which were previously associated with plasma-derived therapies. The leading manufacturers are developing extended half-life recombinant products that reduce the frequency of administration, thus improving patient adherence and outcomes. These developments are driving the adoption of recombinant coagulation factors, especially in developed markets. - Increased Adoption of Prophylactic Treatments:
Prophylactic treatment regimens are increasingly becoming the norm, especially for more severe cases of hemophilia. Prophylaxis has been proven to significantly reduce the risk of bleeding episodes and joint damage, which translates to a better quality of life for patients. Organizations like the WFH and the National Hemophilia Foundation promote early and consistent prophylactic care, which results in increased demand for coagulation factors. This trend is highly prevalent in developed countries with a strong healthcare system.
- Emergence of Gene Therapy for Hemophilia: Gene therapy is changing the face of the treatment of hemophilia, in hopes of providing a cure by giving the body a chance to manufacture its own coagulation factors. Several gene therapies, including valoctocogene roxaparvovec for hemophilia A, are in or have received approval for clinical trials. These drugs could potentially challenge the status quo of the traditional coagulation factors market, but they could also increase treatment options for patients.
- Increasing Demand in Emerging Markets: Emerging economies are witnessing rapid growth in the coagulation factors market, mainly because of increasing awareness, improvement in healthcare infrastructure, and rising income levels. The governments and healthcare organizations in India, China, and Brazil are increasing access to hemophilia care, including coagulation factor products. This is a great opportunity for market players to establish their presence in these regions.
- Development of Non-Factor Therapies: The most recently introduced, increasingly popular alternatives include non-factor replacement therapies such as monoclonal antibodies, an example of which is emicizumab. Such alternative therapies provide advantages that include less frequent dosing and easier administration, particularly for patients with inhibitors to standard coagulation factors. Such products create competition for the traditional market while stimulating innovation and expansion in the general treatment landscape of bleeding disorders.
- Focus on Personalized Medicine:
The development of personalized medicine approaches in coagulation factor therapies presents a huge growth opportunity. Advances in genetic testing and the identification of biomarkers enable treatment plans tailored to maximize efficacy while minimizing adverse effects. Companies that invest in personalized approaches can differentiate themselves in the competitive market while meeting unmet patient needs. - Government and Non-Profit Initiatives:
Sustainability in improving access to coagulation factor therapies is gained in light of support received from governments and nonprofit organizations. Humanitarian Aid Program by WFH supplies factor concentrates to disadvantaged populations, hence fueling the growth of the market in underprivileged regions. Manufacturers collaborating with these efforts can boost their market presence while propelling universal healthcare development. - Technology Gains in Manufacturing:
The coagulation factors can be enhanced by scaling production while making coagulation factors less expensive in light of current developments in the field of biomanufacturing technologies. Recent developments include use of recombinant DNA and cell culture technologies for high purity.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Coagulation Factors Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Coagulation Factors Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Coagulation Factors Market is expected to register a CAGR of 6% from 2025-2031.
The major driving factors supporting Coagulation Factors Market growth are - Rising Prevalence of Hemophilia and Bleeding Disorders, Advancements in Recombinant Coagulation Factor Products, Increased Adoption of Prophylactic Treatments.
Key future trends in the Coagulation Factors Market are - Emergence of Gene Therapy for Hemophilia, Increasing Demand in Emerging Markets, Development of Non-Factor Therapies.
Key companies in the Coagulation Factors Market are - Shire Plc., Baxter International Inc., Grifols International SA, Roche AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, Biogen Idec, Kedrion S.P.A., CSL Ltd., Inc., RayBiotech, Inc., Biotest AG, Diapharma, Enzyme Research Laboratories Ltd., Catalyst Biosciences, Molecular Innovations Inc., Bio Products Laboratory Ltd., Portola Pharmaceuticals
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Coagulation Factors Market - By Product Type
1.3.2 Coagulation Factors Market - By Application
1.3.3 Coagulation Factors Market - By Technology
1.3.4 Coagulation Factors Market - By End User
1.3.5 Coagulation Factors Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. COAGULATION FACTORS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. COAGULATION FACTORS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. COAGULATION FACTORS MARKET - GLOBAL MARKET ANALYSIS
6.1. COAGULATION FACTORS - GLOBAL MARKET OVERVIEW
6.2. COAGULATION FACTORS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. COAGULATION FACTORS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. FACTOR VII
7.3.1. Overview
7.3.2. Factor VII Market Forecast and Analysis
7.4. FACTOR VIII
7.4.1. Overview
7.4.2. Factor VIII Market Forecast and Analysis
7.5. FACTOR IX
7.5.1. Overview
7.5.2. Factor IX Market Forecast and Analysis
7.6. FACTOR X
7.6.1. Overview
7.6.2. Factor X Market Forecast and Analysis
7.7. FACTOR XIII
7.7.1. Overview
7.7.2. Factor XIII Market Forecast and Analysis
7.8. VON WILLEBRAND FACTOR
7.8.1. Overview
7.8.2. Von Willebrand Factor Market Forecast and Analysis
7.9. ANTI-INHIBITOR COAGULANT COMPLEX
7.9.1. Overview
7.9.2. Anti-Inhibitor Coagulant Complex Market Forecast and Analysis
7.10. OTHERS
7.10.1. Overview
7.10.2. Others Market Forecast and Analysis
8. COAGULATION FACTORS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. HEMOPHILIA
8.3.1. Overview
8.3.2. Hemophilia Market Forecast and Analysis
8.4. VON WILLEBRAND DISEASE (VWD)
8.4.1. Overview
8.4.2. Von Willebrand disease (VWD) Market Forecast and Analysis
8.5. SURGERY
8.5.1. Overview
8.5.2. Surgery Market Forecast and Analysis
8.6. OTHER BLEEDING DISORDERS
8.6.1. Overview
8.6.2. Other Bleeding Disorders Market Forecast and Analysis
9. COAGULATION FACTORS MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
9.1. OVERVIEW
9.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
9.3. PLASMA DERIVED
9.3.1. Overview
9.3.2. Plasma derived Market Forecast and Analysis
9.4. RECOMBINANT
9.4.1. Overview
9.4.2. Recombinant Market Forecast and Analysis
10. COAGULATION FACTORS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS AND CLINICS
10.3.1. Overview
10.3.2. Hospitals and Clinics Market Forecast and Analysis
10.4. AMBULATORY SURGERY CENTERS
10.4.1. Overview
10.4.2. Ambulatory Surgery Centers Market Forecast and Analysis
10.5. RESEARCH INSTITUTES
10.5.1. Overview
10.5.2. Research Institutes Market Forecast and Analysis
11. COAGULATION FACTORS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Coagulation Factors Market Overview
11.1.2 North America Coagulation Factors Market Forecasts and Analysis
11.1.3 North America Coagulation Factors Market Forecasts and Analysis - By Product Type
11.1.4 North America Coagulation Factors Market Forecasts and Analysis - By Application
11.1.5 North America Coagulation Factors Market Forecasts and Analysis - By Technology
11.1.6 North America Coagulation Factors Market Forecasts and Analysis - By End User
11.1.7 North America Coagulation Factors Market Forecasts and Analysis - By Countries
11.1.7.1 Mexico Coagulation Factors Market
11.1.7.1.1 Mexico Coagulation Factors Market by Product Type
11.1.7.1.2 Mexico Coagulation Factors Market by Application
11.1.7.1.3 Mexico Coagulation Factors Market by Technology
11.1.7.1.4 Mexico Coagulation Factors Market by End User
11.2. EUROPE
11.2.1 Europe Coagulation Factors Market Overview
11.2.2 Europe Coagulation Factors Market Forecasts and Analysis
11.2.3 Europe Coagulation Factors Market Forecasts and Analysis - By Product Type
11.2.4 Europe Coagulation Factors Market Forecasts and Analysis - By Application
11.2.5 Europe Coagulation Factors Market Forecasts and Analysis - By Technology
11.2.6 Europe Coagulation Factors Market Forecasts and Analysis - By End User
11.2.7 Europe Coagulation Factors Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Coagulation Factors Market
11.2.7.1.1 Germany Coagulation Factors Market by Product Type
11.2.7.1.2 Germany Coagulation Factors Market by Application
11.2.7.1.3 Germany Coagulation Factors Market by Technology
11.2.7.1.4 Germany Coagulation Factors Market by End User
11.2.7.2 France Coagulation Factors Market
11.2.7.2.1 France Coagulation Factors Market by Product Type
11.2.7.2.2 France Coagulation Factors Market by Application
11.2.7.2.3 France Coagulation Factors Market by Technology
11.2.7.2.4 France Coagulation Factors Market by End User
11.2.7.3 Italy Coagulation Factors Market
11.2.7.3.1 Italy Coagulation Factors Market by Product Type
11.2.7.3.2 Italy Coagulation Factors Market by Application
11.2.7.3.3 Italy Coagulation Factors Market by Technology
11.2.7.3.4 Italy Coagulation Factors Market by End User
11.2.7.4 Spain Coagulation Factors Market
11.2.7.4.1 Spain Coagulation Factors Market by Product Type
11.2.7.4.2 Spain Coagulation Factors Market by Application
11.2.7.4.3 Spain Coagulation Factors Market by Technology
11.2.7.4.4 Spain Coagulation Factors Market by End User
11.2.7.5 United Kingdom Coagulation Factors Market
11.2.7.5.1 United Kingdom Coagulation Factors Market by Product Type
11.2.7.5.2 United Kingdom Coagulation Factors Market by Application
11.2.7.5.3 United Kingdom Coagulation Factors Market by Technology
11.2.7.5.4 United Kingdom Coagulation Factors Market by End User
11.2.7.6 Rest of Europe Coagulation Factors Market
11.2.7.6.1 Rest of Europe Coagulation Factors Market by Product Type
11.2.7.6.2 Rest of Europe Coagulation Factors Market by Application
11.2.7.6.3 Rest of Europe Coagulation Factors Market by Technology
11.2.7.6.4 Rest of Europe Coagulation Factors Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Coagulation Factors Market Overview
11.3.2 Asia-Pacific Coagulation Factors Market Forecasts and Analysis
11.3.3 Asia-Pacific Coagulation Factors Market Forecasts and Analysis - By Product Type
11.3.4 Asia-Pacific Coagulation Factors Market Forecasts and Analysis - By Application
11.3.5 Asia-Pacific Coagulation Factors Market Forecasts and Analysis - By Technology
11.3.6 Asia-Pacific Coagulation Factors Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Coagulation Factors Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Coagulation Factors Market
11.3.7.1.1 Australia Coagulation Factors Market by Product Type
11.3.7.1.2 Australia Coagulation Factors Market by Application
11.3.7.1.3 Australia Coagulation Factors Market by Technology
11.3.7.1.4 Australia Coagulation Factors Market by End User
11.3.7.2 China Coagulation Factors Market
11.3.7.2.1 China Coagulation Factors Market by Product Type
11.3.7.2.2 China Coagulation Factors Market by Application
11.3.7.2.3 China Coagulation Factors Market by Technology
11.3.7.2.4 China Coagulation Factors Market by End User
11.3.7.3 India Coagulation Factors Market
11.3.7.3.1 India Coagulation Factors Market by Product Type
11.3.7.3.2 India Coagulation Factors Market by Application
11.3.7.3.3 India Coagulation Factors Market by Technology
11.3.7.3.4 India Coagulation Factors Market by End User
11.3.7.4 Japan Coagulation Factors Market
11.3.7.4.1 Japan Coagulation Factors Market by Product Type
11.3.7.4.2 Japan Coagulation Factors Market by Application
11.3.7.4.3 Japan Coagulation Factors Market by Technology
11.3.7.4.4 Japan Coagulation Factors Market by End User
11.3.7.5 South Korea Coagulation Factors Market
11.3.7.5.1 South Korea Coagulation Factors Market by Product Type
11.3.7.5.2 South Korea Coagulation Factors Market by Application
11.3.7.5.3 South Korea Coagulation Factors Market by Technology
11.3.7.5.4 South Korea Coagulation Factors Market by End User
11.3.7.6 Rest of Asia-Pacific Coagulation Factors Market
11.3.7.6.1 Rest of Asia-Pacific Coagulation Factors Market by Product Type
11.3.7.6.2 Rest of Asia-Pacific Coagulation Factors Market by Application
11.3.7.6.3 Rest of Asia-Pacific Coagulation Factors Market by Technology
11.3.7.6.4 Rest of Asia-Pacific Coagulation Factors Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Coagulation Factors Market Overview
11.4.2 Middle East and Africa Coagulation Factors Market Forecasts and Analysis
11.4.3 Middle East and Africa Coagulation Factors Market Forecasts and Analysis - By Product Type
11.4.4 Middle East and Africa Coagulation Factors Market Forecasts and Analysis - By Application
11.4.5 Middle East and Africa Coagulation Factors Market Forecasts and Analysis - By Technology
11.4.6 Middle East and Africa Coagulation Factors Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Coagulation Factors Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Coagulation Factors Market
11.4.7.1.1 South Africa Coagulation Factors Market by Product Type
11.4.7.1.2 South Africa Coagulation Factors Market by Application
11.4.7.1.3 South Africa Coagulation Factors Market by Technology
11.4.7.1.4 South Africa Coagulation Factors Market by End User
11.4.7.2 Saudi Arabia Coagulation Factors Market
11.4.7.2.1 Saudi Arabia Coagulation Factors Market by Product Type
11.4.7.2.2 Saudi Arabia Coagulation Factors Market by Application
11.4.7.2.3 Saudi Arabia Coagulation Factors Market by Technology
11.4.7.2.4 Saudi Arabia Coagulation Factors Market by End User
11.4.7.3 U.A.E Coagulation Factors Market
11.4.7.3.1 U.A.E Coagulation Factors Market by Product Type
11.4.7.3.2 U.A.E Coagulation Factors Market by Application
11.4.7.3.3 U.A.E Coagulation Factors Market by Technology
11.4.7.3.4 U.A.E Coagulation Factors Market by End User
11.4.7.4 Rest of Middle East and Africa Coagulation Factors Market
11.4.7.4.1 Rest of Middle East and Africa Coagulation Factors Market by Product Type
11.4.7.4.2 Rest of Middle East and Africa Coagulation Factors Market by Application
11.4.7.4.3 Rest of Middle East and Africa Coagulation Factors Market by Technology
11.4.7.4.4 Rest of Middle East and Africa Coagulation Factors Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Coagulation Factors Market Overview
11.5.2 South and Central America Coagulation Factors Market Forecasts and Analysis
11.5.3 South and Central America Coagulation Factors Market Forecasts and Analysis - By Product Type
11.5.4 South and Central America Coagulation Factors Market Forecasts and Analysis - By Application
11.5.5 South and Central America Coagulation Factors Market Forecasts and Analysis - By Technology
11.5.6 South and Central America Coagulation Factors Market Forecasts and Analysis - By End User
11.5.7 South and Central America Coagulation Factors Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Coagulation Factors Market
11.5.7.1.1 Brazil Coagulation Factors Market by Product Type
11.5.7.1.2 Brazil Coagulation Factors Market by Application
11.5.7.1.3 Brazil Coagulation Factors Market by Technology
11.5.7.1.4 Brazil Coagulation Factors Market by End User
11.5.7.2 Argentina Coagulation Factors Market
11.5.7.2.1 Argentina Coagulation Factors Market by Product Type
11.5.7.2.2 Argentina Coagulation Factors Market by Application
11.5.7.2.3 Argentina Coagulation Factors Market by Technology
11.5.7.2.4 Argentina Coagulation Factors Market by End User
11.5.7.3 Rest of South and Central America Coagulation Factors Market
11.5.7.3.1 Rest of South and Central America Coagulation Factors Market by Product Type
11.5.7.3.2 Rest of South and Central America Coagulation Factors Market by Application
11.5.7.3.3 Rest of South and Central America Coagulation Factors Market by Technology
11.5.7.3.4 Rest of South and Central America Coagulation Factors Market by End User
12. IMPACT OF COVID-19 PANDEMIC ON GLOBAL COAGULATION FACTORS MARKET
12.1 North America
12.2 Europe
12.3 Asia-Pacific
12.4 Middle East and Africa
12.5 South and Central America
13. INDUSTRY LANDSCAPE
13.1. MERGERS AND ACQUISITIONS
13.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
13.3. NEW PRODUCT LAUNCHES
13.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
14. COAGULATION FACTORS MARKET, KEY COMPANY PROFILES
14.1. SHIRE PLC.
14.1.1. Key Facts
14.1.2. Business Description
14.1.3. Products and Services
14.1.4. Financial Overview
14.1.5. SWOT Analysis
14.1.6. Key Developments
14.2. BAXTER INTERNATIONAL INC.
14.2.1. Key Facts
14.2.2. Business Description
14.2.3. Products and Services
14.2.4. Financial Overview
14.2.5. SWOT Analysis
14.2.6. Key Developments
14.3. GRIFOLS INTERNATIONAL SA
14.3.1. Key Facts
14.3.2. Business Description
14.3.3. Products and Services
14.3.4. Financial Overview
14.3.5. SWOT Analysis
14.3.6. Key Developments
14.4. ROCHE AG
14.4.1. Key Facts
14.4.2. Business Description
14.4.3. Products and Services
14.4.4. Financial Overview
14.4.5. SWOT Analysis
14.4.6. Key Developments
14.5. BAYER AG
14.5.1. Key Facts
14.5.2. Business Description
14.5.3. Products and Services
14.5.4. Financial Overview
14.5.5. SWOT Analysis
14.5.6. Key Developments
14.6. PFIZER INC.
14.6.1. Key Facts
14.6.2. Business Description
14.6.3. Products and Services
14.6.4. Financial Overview
14.6.5. SWOT Analysis
14.6.6. Key Developments
14.7. NOVO NORDISK A/S
14.7.1. Key Facts
14.7.2. Business Description
14.7.3. Products and Services
14.7.4. Financial Overview
14.7.5. SWOT Analysis
14.7.6. Key Developments
14.8. OCTAPHARMA AG
14.8.1. Key Facts
14.8.2. Business Description
14.8.3. Products and Services
14.8.4. Financial Overview
14.8.5. SWOT Analysis
14.8.6. Key Developments
14.9. BIOGEN IDEC
14.9.1. Key Facts
14.9.2. Business Description
14.9.3. Products and Services
14.9.4. Financial Overview
14.9.5. SWOT Analysis
14.9.6. Key Developments
14.10. KEDRION S.P.A.
14.10.1. Key Facts
14.10.2. Business Description
14.10.3. Products and Services
14.10.4. Financial Overview
14.10.5. SWOT Analysis
14.10.6. Key Developments
15. APPENDIX
15.1. ABOUT THE INSIGHT PARTNERS
15.2. GLOSSARY OF TERMS
1. Shire Plc.
2. Baxter International Inc.
3. Grifols International SA
4. Roche AG
5. Bayer AG
6. Pfizer Inc.
7. Novo Nordisk A/S
8. Octapharma AG
9. Biogen Idec
10. Kedrion S.P.A.
11. CSL Ltd., Inc.
12. RayBiotech, Inc.
13. Biotest AG
14. Diapharma
15. Enzyme Research Laboratories Ltd.
16. Catalyst Biosciences
17. Molecular Innovations Inc.
18. Bio Products Laboratory Ltd.
19. Portola Pharmaceuticals
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For